| 1 |
Sant´anna FM, Araújo-pereira M, Schmaltz CAS, Arriaga MB, de Oliveira RVC, Andrade BB, Rolla VC. Adverse Drug Reactions Related to Treatment of Drug-Susceptible Tuberculosis in Brazil: A Prospective Cohort Study. Front Trop Dis 2022;2:748310. [DOI: 10.3389/fitd.2021.748310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Singh A, Meena P, Dabas A, Yadav S, Agarwal A, Khanna V, Khanna A. Hepatotoxicity associated with first-line antitubercular drugs in children at a tertiary care facility. Indian Journal of Tuberculosis 2022;69:1-3. [DOI: 10.1016/j.ijtb.2021.06.008] [Reference Citation Analysis]
|
| 3 |
Satsangi S, Randev S, Taneja S. Antitubercular Therapy-Related Hepatitis. Tuberculosis of the Gastrointestinal system 2022. [DOI: 10.1007/978-981-16-9053-2_23] [Reference Citation Analysis]
|
| 4 |
Liu YH, Guo Y, Xu H, Feng H, Chen DY. Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury. Infect Drug Resist 2021;14:3667-71. [PMID: 34526786 DOI: 10.2147/IDR.S326386] [Reference Citation Analysis]
|
| 5 |
Herawati F, Fahmi EY, Pratiwi NA, Ramdani D, Jaelani AK, Yulia R, Andrajati R. Oral anti-tuberculosis drugs: An urgent medication reconciliation at hospitals in Indonesia. J Public Health Res 2021;10. [PMID: 34463088 DOI: 10.4081/jphr.2021.1896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Zhong T, Zhuang Z, Dong X, Wong KH, Wong WT, Wang J, He D, Liu S. Predicting Antituberculosis Drug-Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study. JMIR Med Inform 2021;9:e29226. [PMID: 34283036 DOI: 10.2196/29226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Dorval G, Berteloot L, Pio L, Boyer O, Blanc T. A rare cause of transitory hematuria and urinary tract dysfunction in children: Answers. Pediatr Nephrol 2021;36:2131-5. [PMID: 33768327 DOI: 10.1007/s00467-021-05006-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Jiang F, Yan H, Liang L, Du J, Jin S, Yang S, Wang H, Hu T, Zhu Y, Wang G, Hu Y, Cai T, Aithal GP. Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. Liver Int 2021;41:1565-75. [PMID: 33866661 DOI: 10.1111/liv.14896] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 9 |
Irabien M, Blanco S, Calderón Á. DRESS syndrome and drug-induced liver injury owing to antituberculous treatment. Gastroenterología y Hepatología (English Edition) 2021;44:427-428. [DOI: 10.1016/j.gastre.2020.07.016] [Reference Citation Analysis]
|
| 10 |
Rens NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, Croda J, Andrews JR. Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. Clin Infect Dis 2020;71:3136-43. [PMID: 31905381 DOI: 10.1093/cid/ciz1212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 11 |
Park JH, Hong S, Jun DW, Yoon JH, Lee KN, Lee HL, Lee OY, Yoon BC, Choi HS. Prevalence and clinical characteristics of antibiotics associated drug induced liver injury. Ann Transl Med 2021;9:642. [PMID: 33987340 DOI: 10.21037/atm-20-5144] [Reference Citation Analysis]
|
| 12 |
Zhong T, Zhuang Z, Dong X, Wong KH, Wong WT, Wang J, He D, Liu S. Predicting Antituberculosis Drug–Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study (Preprint).. [DOI: 10.2196/preprints.29226] [Reference Citation Analysis]
|
| 13 |
Cresswell FV, Meya DB, Kagimu E, Grint D, Te Brake L, Kasibante J, Martyn E, Rutakingirwa M, Quinn CM, Okirwoth M, Tugume L, Ssembambulidde K, Musubire AK, Bangdiwala AS, Buzibye A, Muzoora C, Svensson EM, Aarnoutse R, Boulware DR, Elliott AM. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clin Infect Dis 2021;73:876-84. [PMID: 33693537 DOI: 10.1093/cid/ciab162] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 14 |
Niu H, Sanabria-cabrera J, Alvarez-alvarez I, Robles-diaz M, Stankevičiūtė S, Aithal GP, Björnsson ES, Andrade RJ, Lucena MI. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacological Research 2021;164:105404. [DOI: 10.1016/j.phrs.2020.105404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 15 |
Patterson B, Abbara A, Collin S, Henderson M, Shehata M, Gorgui-Naguib H, Lynn W, Kon OM, John L. Predicting drug-induced liver injury from anti-tuberculous medications by early monitoring of liver tests. J Infect 2021;82:240-4. [PMID: 33271167 DOI: 10.1016/j.jinf.2020.09.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 16 |
Kesenogile B, Godman B, Rwegerera GM. Alanine transaminase and hemoglobin appear to predict the occurrence of antituberculosis medication hepatotoxicity; findings and implications in Botswana. Expert Rev Anti Infect Ther 2021;19:379-91. [PMID: 32909487 DOI: 10.1080/14787210.2020.1822735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 17 |
Ngah YE, Cho FN, Etagha BS, Fusi NG, Francisca N, Ikomey MG, Ibrahim N. Incidence and Risk Factors of Combined-Antiretroviral Therapy-Induced Hepatotoxicity among HIV Patients at the Bali District Hospital, Cameroon.. [DOI: 10.1101/2020.11.16.384339] [Reference Citation Analysis]
|
| 18 |
Irabien M, Blanco S, Calderón Á. DRESS syndrome and drug-induced liver injury owing to antituberculous treatment. Gastroenterol Hepatol 2021;44:427-8. [PMID: 33168228 DOI: 10.1016/j.gastrohep.2020.07.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 19 |
Kang W, Du J, Yang S, Yu J, Chen H, Liu J, Ma J, Li M, Qin J, Shu W, Zong P, Zhang Y, Dong Y, Yang Z, Mei Z, Deng Q, Wang P, Han W, Wu M, Chen L, Zhao X, Tan L, Li F, Zheng C, Liu H, Li X, Ertai A, Du Y, Liu F, Cui W, Wang Q, Chen X, Han J, Xie Q, Feng Y, Liu W, Tang P, Zhang J, Zheng J, Chen D, Yao X, Ren T, Li Y, Li Y, Wu L, Song Q, Yang M, Zhang J, Liu Y, Guo S, Yan K, Shen X, Lei D, Zhang Y, Yan X, Li L, Tang S. The prevalence and risks of major comorbidities among inpatients with pulmonary tuberculosis in China from a gender and age perspective: a large-scale multicenter observational study. Eur J Clin Microbiol Infect Dis 2021;40:787-800. [PMID: 33094354 DOI: 10.1007/s10096-020-04077-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 20 |
Teschke R, Danan G. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis. Medicines (Basel) 2020;7:E62. [PMID: 33003400 DOI: 10.3390/medicines7100062] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 21 |
Xu N, Yang JX, Yang J. Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China. Eur J Hosp Pharm. [DOI: 10.1136/ejhpharm-2020-002433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 22 |
Beck-friis J, Studahl M, Yilmaz A, Andersson R, Lönnermark E. Increased risk of hepatotoxicity and temporary drug withdrawal during treatment of active tuberculosis in pregnant women. International Journal of Infectious Diseases 2020;98:138-43. [DOI: 10.1016/j.ijid.2020.06.069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Moosa MS, Maartens G, Gunter H, Allie S, Chughlay MF, Setshedi M, Wasserman S, Hickman N, Stewart A, Sonderup M, Spearman CW, Cohen K. A Randomized Controlled Trial of Intravenous N-acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. Clin Infect Dis 2020:ciaa1255. [PMID: 32845997 DOI: 10.1093/cid/ciaa1255] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 24 |
Chang TE, Huang YS, Su WJ, Perng CL, Huang YH, Hou MC. The role of regular liver function monitoring in antituberculosis drug-induced liver injury. J Chin Med Assoc 2019;82:535-40. [PMID: 31274784 DOI: 10.1097/JCMA.0000000000000119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 25 |
Pandey J, Madaan P, Saini L, Verma S. Anti-tuberculous drug induced liver injury - Do we need to rethink? Indian J Tuberc 2020;67:260-1. [PMID: 32553322 DOI: 10.1016/j.ijtb.2019.09.006] [Reference Citation Analysis]
|
| 26 |
Goh ZH, Tee JK, Ho HK. An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage. Int J Mol Sci 2020;21:E3714. [PMID: 32466226 DOI: 10.3390/ijms21103714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 27 |
Enoh JE, Cho FN, Manfo FP, Ako SE, Akum EA. Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon. Biomed Res Int 2020;2020:9631731. [PMID: 32462039 DOI: 10.1155/2020/9631731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 28 |
Liu Y, Zhan SP, Song L, Chen Y, Jia YT, Liu F, Sun FJ, Wang Q, Xia PY. Drug-Induced Liver Injury: Clinical and Etiologic Features at a Large Tertiary Teaching Hospital in China. Med Sci Monit 2020;26:e919435. [PMID: 32172275 DOI: 10.12659/MSM.919435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 29 |
Zhao H, Wang Y, Zhang T, Wang Q, Xie W. Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study. Med Sci Monit 2020;26:e920350. [PMID: 32145061 DOI: 10.12659/MSM.920350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 30 |
Soni H, Kumar-m P, Mishra S, Bellam BL, Singh H, Mandavdhare HS, Medhi B, Dutta U, Sharma V. Risk of hepatitis with various reintroduction regimens of anti-tubercular therapy: a systematic review and network meta-analysis. Expert Review of Anti-infective Therapy 2020;18:171-9. [DOI: 10.1080/14787210.2020.1714436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 31 |
Авербах ММ. ГЕПАТОТОКСИЧЕСКИЕ РЕАКЦИИ У БОЛЬНЫХ ТУБЕРКУЛЕЗОМ НА ОСНОВНЫЕ ПРОТИВОТУБЕРКУЛЕЗНЫЕ ХИМИОПРЕПАРАТЫ. СОСТОЯНИЕ ПРОБЛЕМЫ, "Вестник Центрального научно-исследовательского института туберкулеза". Вестник ЦНИИТ 2020. [DOI: 10.7868/s258766782002003x] [Reference Citation Analysis]
|
| 32 |
Mallet M, Saliba F. Chronic alcohol consumption, a novel risk factor of liver transplantation or death in patients with acute liver failure. Liver Int 2020;40:45-6. [PMID: 31872578 DOI: 10.1111/liv.14169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 33 |
Lin S, Zhao S, Liu J, Zhang J, Zhang C, Hao H, Sun Y, Cai J, Yang Y, Ma Y, Li Y, Wang J, Ma A. Efficacy of proprietary Lactobacillus casei for anti-tuberculosis associated gastrointestinal adverse reactions in adult patients: a randomized, open-label, dose–response trial. Food Funct 2020;11:370-7. [DOI: 10.1039/c9fo01583c] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 34 |
Gafar F, Van't Boveneind-Vrubleuskaya N, Akkerman OW, Wilffert B, Alffenaar JC. Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands. Eur Respir J 2019;54:1901402. [PMID: 31515410 DOI: 10.1183/13993003.01402-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 35 |
Cerrone M, Bracchi M, Wasserman S, Pozniak A, Meintjes G, Cohen K, Wilkinson RJ. Safety implications of combined antiretroviral and anti-tuberculosis drugs. Expert Opin Drug Saf 2020;19:23-41. [PMID: 31809218 DOI: 10.1080/14740338.2020.1694901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 36 |
Lakshmi K, Raj V. A Concise Review on Incidence and Risk Factors for Antituberculous Treatment-induced Hepatotoxicity. Annals of SBV 2019;8:38-41. [DOI: 10.5005/jp-journals-10085-8108] [Reference Citation Analysis]
|
| 37 |
Nataprawira HM, Pratama AA, Widiasta A, Sibarani J, Hilmanto D, Sekarwana N, Rachmadi D. Complicated Urinary Tract Tuberculosis in a 13-Year-Old Adolescent with Chronic Kidney Disease and Antituberculous Drug-Induced Hepatotoxicity. Case Rep Infect Dis 2019;2019:7370150. [PMID: 31781434 DOI: 10.1155/2019/7370150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 38 |
Goh Z, Tee JK, Ho HK. An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage.. [DOI: 10.1101/815241] [Reference Citation Analysis]
|
| 39 |
Puga MAM, Bandeira LM, Pompilio MA, Rezende GR, Soares LS, de Castro VOL, Tanaka TSO, Cesar GA, de Oliveira SMDVL, Teles SA, Yassuda RTS, Weis-Torres SMDS, Basílio SF, Croda J, Motta-Castro ARC. Screening for HBV, HCV, HIV and syphilis infections among bacteriologically confirmed tuberculosis prisoners: An urgent action required. PLoS One 2019;14:e0221265. [PMID: 31437184 DOI: 10.1371/journal.pone.0221265] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 40 |
Teschke R. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. Front Pharmacol 2019;10:730. [PMID: 31396080 DOI: 10.3389/fphar.2019.00730] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 41 |
Nagarajan S, Whitaker P. Management of adverse reactions to first-line tuberculosis antibiotics. Curr Opin Allergy Clin Immunol 2018;18:333-41. [PMID: 29901473 DOI: 10.1097/ACI.0000000000000462] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 42 |
Mathew JL. Association between ATT and Hepatotoxicity: Food for Thought. Indian J Pediatr 2019;86:211-3. [PMID: 30762203 DOI: 10.1007/s12098-019-02899-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 43 |
Dawra S, Mandavdhare HS, Singh H, Prasad KK, Dutta U, Sharma V. Extra-abdominal involvement is associated with antitubercular therapy-related hepatitis in patients treated for abdominal tuberculosis. Clin Exp Hepatol 2019;5:60-4. [PMID: 30915408 DOI: 10.5114/ceh.2019.83158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 44 |
Pau AK, Kuriakose S, Dooley KE, Maartens G. Treatment of Drug-Sensitive Tuberculosis in Persons with HIV. HIV and Tuberculosis 2019. [DOI: 10.1007/978-3-030-29108-2_9] [Reference Citation Analysis]
|
| 45 |
Nwidu LL, Oboma YI. Telfairia occidentalis (Cucurbitaceae) pulp extract mitigates rifampicin-isoniazid-induced hepatotoxicity in an in vivo rat model of oxidative stress. J Integr Med 2019;17:46-56. [PMID: 30555014 DOI: 10.1016/j.joim.2018.11.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 46 |
Sivannan S, Vishnuvardhan A, Elumalai K, Srinivasan S, Eluri K, Elumalai M, Muthu R. Isoniazid‐induced liver disorder in the treatment of tuberculosis. Chronic Diseases and Translational Medicine 2018;4:268-270. [DOI: 10.1016/j.cdtm.2018.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 47 |
Darvin SS, Esakkimuthu S, Toppo E, Balakrishna K, Paulraj MG, Pandikumar P, Ignacimuthu S, Al-dhabi N. Hepatoprotective effect of lawsone on rifampicin-isoniazid induced hepatotoxicity in in vitro and in vivo models. Environmental Toxicology and Pharmacology 2018;61:87-94. [DOI: 10.1016/j.etap.2018.05.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 48 |
Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:819-32. [PMID: 29556685 DOI: 10.1007/s00228-018-2441-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
|
